Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus–Associated Oropharyngeal Carcinoma
JCO Oncology Practice · 2026-11 · 22 (11) · 1888-1890
DOI: 10.1200/op-25-01201 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Oncology Practice, 2026-11. Verfasst von Ross D Merkin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute, Boston, MA. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Mass General Brigham Cancer Institute, Boston, MA.
- Massachusetts General Hospital, Boston, MA.
- Massachusetts Eye and Ear, Boston, MA.
- Department of Medicine, Harvard Medical School, Boston, MA.
- Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA.
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
ORCID-Profile: Ross D Merkin, Daniel L Faden, Lori J Wirth
Zitieren
APA
Merkin, R. D., Faden, D. L., & Wirth, L. J. (2026). Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus–Associated Oropharyngeal Carcinoma. JCO Oncology Practice, 22(11), 1888-1890. https://doi.org/10.1200/op-25-01201
Vancouver
Merkin RD, Faden DL, Wirth LJ. Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus–Associated Oropharyngeal Carcinoma. JCO Oncology Practice. 2026;22(11):1888-1890. doi:10.1200/op-25-01201
BibTeX
@article{Merkin2026,
author = {Merkin, Ross D and Faden, Daniel L and Wirth, Lori J},
title = {Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus–Associated Oropharyngeal Carcinoma},
journal = {JCO Oncology Practice},
year = {2026},
volume = {22},
number = {11},
pages = {1888--1890},
doi = {10.1200/op-25-01201}
}
EUVIMED